Home
Live Updates
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy : comparemela.com
Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
PRINCETON, N.J. & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Feb 16, 2024--
Related Keywords
Japan ,
Massachusetts ,
United States ,
Tokyo ,
Barrattj Ig ,
Robert Murphy ,
Jeffrey Gilbert ,
John Kraus ,
Christopher Kiefer ,
Brian Jg Pereira ,
Otsuka Pharmaceutical Co Ltd ,
Corporate Communications ,
Visterra Inc ,
Otsuka America Inc ,
Twitter ,
Otsuka Pharmaceutical Development Commercialization Inc ,
Glomerular Diseases Work Group ,
Otsuka America Pharmaceutical Inc ,
Drug Administration ,
Otsuka Pharmaceutical Company Ltd ,
Otsuka Holdings Co Ltd ,
Linkedin ,
Pharmaceutical Development ,
Otsuka Pharmaceutical ,
Breakthrough Therapy ,
New England Journal ,
Biological Licensing Application ,
Proliferation Inducing Ligand ,
Otsuka Pharmaceutical Development ,
Otsuka America Pharmaceutical ,
Otsuka Pharmaceutical Company ,
Otsuka America ,
Immune Modulation ,
Iga Nephropathy ,
Neutralizing Igg ,
Kidney Int ,
Patients From ,
Southeastern United States With Iga ,
Rev Dis ,
Improving Global Outcomes ,
Glomerular Diseases Work ,
Practice Guideline ,
America Pharmaceutical ,
Business Wire ,
Region ,
comparemela.com © 2020. All Rights Reserved.